Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc. reports a significant milestone in its bladder cancer clinical study, with over 60% of patients achieving a complete response and 35.6% maintaining this response for three years or more. The company’s lead drug, Ruvidar, used alongside the TLC-3200 Medical Laser System, is currently in a Phase II study for a form of bladder cancer with high treatment failure rates, addressing an urgent medical need.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
